Deprescribing Antipsychotics: a Multiple Case Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07343193

Acronym

DEPRESC

Enrollment

Registered

2026-01-15

Start date

2025-09-09

Completion date

2026-09-09

Last updated

2026-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psychotic Disorder

Keywords

Psychotic Disorder, Psychotic or Related Disorder, Antipsychotics

Brief summary

The literature on antipsychotic deprescribing highlights the difficulty in establishing a clear consensus on the most optimal strategy due to the diversity of clinical situations encountered in daily practice: who should be deprescribed, when, at what rate, what strategy to employ in case of relapse, etc. The fear of relapse leads psychiatrists (particularly in France) to tend to maintain long-term treatment, even if the arguments for this maintenance may be debatable due to an uncertain benefit-risk balance. Conversely, patients often request a reduction or discontinuation, notably because of the side effects of the treatments. This argument serves to justify the value of presenting unique clinical situations like those in this study in a publication. The goal is for readers to gain a practical understanding of the successes and difficulties of deprescribing in real-life situations.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adults (≥18 years) * Patients with a psychotic or related disorder * Patients on long-term antipsychotic treatment, clinically stable, who accept or request a deprescription between January 1, 2021, and October 30, 2025

Exclusion criteria

\- Patients who have expressed their opposition to participating in the study

Design outcomes

Primary

Measure	Time frame	Description
Describe clinical situations where discontinuation of antipsychotics or a reduction of antipsychotics below the theoretically minimum recommended doses was possible.	Up to 12 months	Stopping or reducing treatment: * Some patients may do well with less medication, * or even without medication, under carefully monitored conditions.

Countries

France

Contacts

Primary ContactFabrice BERNA, MD, PhD

fabrice.berna@chru-strasbourg.fr33 3 88 11 64 62

Outcome results